Experienced in Alveolar Soft Part Sarcoma

Dr. Joaquina C. Baranda

Oncology
University Of Kansas Hospital Authority
2650 Shawnee Mission Pkwy, 
Westwood, KS 
Accepting New Patients
Experienced in Alveolar Soft Part Sarcoma
University Of Kansas Hospital Authority
2650 Shawnee Mission Pkwy, 
Westwood, KS 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Joaquina Baranda is an Oncologist in Westwood, Kansas. Dr. Baranda is rated as an Experienced provider by MediFind in the treatment of Alveolar Soft Part Sarcoma. Her top areas of expertise are Colorectal Cancer, Pancreatic Cancer, Familial Colorectal Cancer, and Familial Pancreatic Cancer. Dr. Baranda is currently accepting new patients.

Her clinical research consists of co-authoring 34 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Oncology
Licenses
Internal Medicine in KS
Hospital Affiliations
University Of Kansas Hospital
Languages Spoken
English
Filipino
Spanish
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Home State Health
  • EPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Oscar
  • EPO
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 4 Less Insurance Carriers -

Locations

UNIVERSITY OF KANSAS HOSPITAL AUTHORITY
2650 Shawnee Mission Pkwy, Westwood, KS 66205

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Phase 2 Study of AZD1775 in SETD2-Deficient Advanced Solid Tumor Malignancies
A Phase 2 Study of AZD1775 in SETD2-Deficient Advanced Solid Tumor Malignancies
Enrollment Status: Active_not_recruiting
Publish Date: September 03, 2025
Intervention Type: Drug
Study Drug: Adavosertib
Study Phase: Phase 2
A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients With Stage 0-III Colon or Rectal Cancer, Phase III - Preventing Adenomas of the Colon With Eflornithine and Sulindac (PACES)
A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients With Stage 0-III Colon or Rectal Cancer, Phase III - Preventing Adenomas of the Colon With Eflornithine and Sulindac (PACES)
Enrollment Status: Active_not_recruiting
Publish Date: March 30, 2025
Intervention Type: Drug
Study Phase: Phase 3
A Phase I, First-in-human, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-0184 Administered Once Weekly for 4 Weeks to Patients With Advanced Solid Tumors
A Phase I, First-in-human, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-0184 Administered Once Weekly for 4 Weeks to Patients With Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: November 14, 2023
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1a / 1b, First-in-human, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-0903 Administered Daily for 21 Days to Patients With Advanced Solid Tumors
A Phase 1a / 1b, First-in-human, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-0903 Administered Daily for 21 Days to Patients With Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: November 14, 2023
Intervention Type: Drug
Study Drug: TP-0903
Study Phase: Phase 1
Phase II Pilot Study of FOLFOXIRI Plus Panitumumab in Metastatic RAS Wild-type, Left-sided Colorectal Cancer
Phase II Pilot Study of FOLFOXIRI Plus Panitumumab in Metastatic RAS Wild-type, Left-sided Colorectal Cancer
Enrollment Status: Unknown
Publish Date: July 27, 2023
Intervention Type: Drug
Study Phase: Phase 2
A Phase 1, Multicenter, Open-Label, Dose Escalation and Dose Expansion Study of SQZ-PBMC-HPV as Monotherapy and in Combination With Atezolizumab or Other Immune Checkpoint Inhibitors in HLA-A*02+ Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors
A Phase 1, Multicenter, Open-Label, Dose Escalation and Dose Expansion Study of SQZ-PBMC-HPV as Monotherapy and in Combination With Atezolizumab or Other Immune Checkpoint Inhibitors in HLA-A*02+ Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors
Enrollment Status: Completed
Publish Date: April 14, 2023
Intervention Type: Drug, Biological
Study Drugs: SQZ-PBMC-HPV, Atezolizumab, Ipilimumab, Nivolumab
Study Phase: Phase 1
A Prospective Longitudinal Study of CA 19-9 as an Aid in Monitoring Disease in Patients With Pancreatic Cancer
A Prospective Longitudinal Study of CA 19-9 as an Aid in Monitoring Disease in Patients With Pancreatic Cancer
Enrollment Status: Completed
Publish Date: August 17, 2021
Intervention Type: Other
View 6 Less Clinical Trials

34 Total Publications

Enfortumab vedotin in patients with advanced non-small cell lung cancer after disease progression on platinum- and PD-1/PD-L1 inhibitor-containing regimens: Phase 2 international multicenter EV-202 study.
Enfortumab vedotin in patients with advanced non-small cell lung cancer after disease progression on platinum- and PD-1/PD-L1 inhibitor-containing regimens: Phase 2 international multicenter EV-202 study.
Journal: European journal of cancer (Oxford, England : 1990)
Published: March 31, 2025
Similar Doctors
Distinguished in Alveolar Soft Part Sarcoma
Dr. Benjamin Powers
Hematology Oncology | Hematology | Oncology
Distinguished in Alveolar Soft Part Sarcoma
Dr. Benjamin Powers
Hematology Oncology | Hematology | Oncology

University Of Kansas Hospital Authority

3901 Rainbow Blvd, 
Kansas City, KS 
 (1.8 miles away)
913-588-7743
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Benjamin Powers is a Hematologist Oncology specialist and a Hematologist in Kansas City, Kansas. Dr. Powers is rated as a Distinguished provider by MediFind in the treatment of Alveolar Soft Part Sarcoma. His top areas of expertise are Adult Soft Tissue Sarcoma, Liposarcoma, Angiosarcoma of the Scalp, Synovial Sarcoma, and Tissue Biopsy.

Advanced in Alveolar Soft Part Sarcoma
Dr. Larry R. Corum
Hematology Oncology | Hematology | Oncology
Advanced in Alveolar Soft Part Sarcoma
Dr. Larry R. Corum
Hematology Oncology | Hematology | Oncology

Kansas University Physicians Inc

20333 W 151st St, Olathe Medical Center, 
Olathe, KS 
 (16.7 miles away)
913-588-1227
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Larry Corum is a Hematologist Oncology specialist and a Hematologist in Olathe, Kansas. Dr. Corum is rated as a Distinguished provider by MediFind in the treatment of Alveolar Soft Part Sarcoma. His top areas of expertise are Chronic Lymphocytic Leukemia (CLL), Richter Syndrome, Chronic B-Cell Leukemia (CBCL), and Lung Cancer. Dr. Corum is currently accepting new patients.

Advanced in Alveolar Soft Part Sarcoma
Dr. Gary Doolittle
Hematology | Oncology
Advanced in Alveolar Soft Part Sarcoma
Dr. Gary Doolittle
Hematology | Oncology

University Of Kansas Hospital Authority

2650 Shawnee Mission Pkwy, 
Westwood, KS 
 (0.1 miles away)
913-588-7750
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Gary Doolittle is a Hematologist and an Oncologist in Westwood, Kansas. Dr. Doolittle is rated as a Distinguished provider by MediFind in the treatment of Alveolar Soft Part Sarcoma. His top areas of expertise are Melanoma, Merkel Cell Carcinoma, Rhabdomyosarcoma Embryonal, and Bone Tumor.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Baranda's expertise for a condition
ConditionClose
    View All 7 Advanced Conditions
    View All 53 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile